LFB is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.
The completion of the sale comes as part of LFB’s strategy to refocus on its core business – medicinal products derived from plasma or recombinant proteins Les Ulis (France), 1st April 2019 – LFB announces the completion of the sale of CELLforCURE to Novartis.